What is Protean BioDiagnostics?
Protean BioDiagnostics operates at the intersection of biotechnology and big data, providing a comprehensive ecosystem for cancer care. Its flagship offering, Oncology MAPS, serves as a fully integrated diagnostic system that synthesizes digital pathology, multi-omics, and artificial intelligence to deliver actionable insights. Beyond its diagnostic suite, the company maintains CAP-accredited and CLIA-certified laboratories, facilitating robust support for clinical trials, biomarker development, and the rapid deployment of companion diagnostics. By bridging the gap between complex genetic testing and clinical application, Protean is effectively democratizing access to precision medicine for oncologists and their patients globally.
Core keywords: precision oncology, cancer diagnostics, Oncology MAPS, biotechnology, molecular testing, artificial intelligence, clinical trials, biomarker development, diagnostic infrastructure.
How much funding has Protean BioDiagnostics raised?
Protean BioDiagnostics has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2025): $150K with participation from Celtic Bank
Key Investors in Protean BioDiagnostics
Celtic Bank
A specialized financial institution providing commercial lending and capital solutions to support the growth of innovative technology and healthcare enterprises.
What's next for Protean BioDiagnostics?
With this late-stage capital, Protean BioDiagnostics is poised to scale its operational footprint and enhance its data-driven diagnostic capabilities. The strategic focus will likely center on expanding the reach of its Oncology MAPS platform, further integrating AI-driven analytics to refine patient monitoring and treatment selection. As the company continues to leverage its global research networks, the focus will shift toward strengthening its position as a critical partner for pharmaceutical firms in companion diagnostic development. This growth trajectory suggests a move toward broader market penetration and the solidification of its diagnostic ecosystem as a standard for community-based cancer care.
See full Protean BioDiagnostics company page
